^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Urothelial Cancer
    Drug:zelenectide pevedotin (BT8009) (Microtubule inhibitor, Nectin-4-targeted peptide-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Bicycle Therapeutics Press Release
    Title:

    Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer

    Published date:
    01/04/2023
    Excerpt:
    Bicycle Therapeutics plc...announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle’s BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.